David Witty, MD
Pulmonary Disease · Tupelo, MSNPI 1114984374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,630 and has fallen 98.7% since, to $21 in 2025.
Across 380 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Boehringer Ingelheim$688
- Insmed, Inc.$413
- Novartis$264
- Harmony Biosciences LLC$262
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,35797%
- Education$1743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 114 | $1,332 |
| AstraZeneca | 46 | $1,234 |
| Boehringer Ingelheim | 42 | $688 |
| Insmed, Inc. | 14 | $413 |
| Novartis | 16 | $264 |
| Harmony Biosciences LLC | 13 | $262 |
| Mallinckrodt Hospital Products Inc. | 12 | $217 |
| Genentech USA, Inc. | 14 | $191 |
| Merck | 11 | $189 |
| Sanofi | 10 | $185 |
| Actelion Pharmaceuticals US, Inc. | 10 | $183 |
| Bayer | 9 | $149 |
| Jazz Pharmaceuticals Inc. | 7 | $134 |
| Mylan Specialty L.p. | 7 | $118 |
| Sunovion Pharmaceuticals Inc. | 11 | $108 |
| Regeneron Healthcare Solutions, Inc. | 5 | $103 |
| ANI Pharmaceuticals, Inc. | 2 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Mallinckrodt Enterprises LLC | 4 | $68 |
| Astellas Pharma US Inc | 3 | $60 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $53 |
| La Jolla Pharmaceutical Company | 4 | $51 |
| Medtronic | 1 | $44 |
| Pulmonx Corporation | 2 | $39 |
| Philips North America LLC | 2 | $35 |
| Amgen | 2 | $30 |
| Gilead | 2 | $29 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Electromed, Inc. | 1 | $21 |
| United Therapeutics Corporation | 1 | $21 |
| Ambu Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| AbbVie | 1 | $17 |
| Aerin Medical Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $14 |
| Monaghan Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,531 in reported general payments places this provider in the 55th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 18 | $214,376 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 201 | $160,791 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 11 | $160,142 |
| NucalaMepolizumab | 24 | $87,797 |
| XolairOmalizumab | 30 | $60,518 |
| Breo ElliptaFluticasone/Vilanterol | 120 | $51,550 |
| Ambrisentan | 16 | $45,322 |
| Spiriva RespimatTiotropium Bromide | 49 | $33,566 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $28,650 |
| Arnuity ElliptaFluticasone Furoate | 91 | $23,939 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $22,442 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $17,956 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $14,861 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $13,526 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $10,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,332 | $370,683540 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $688 | $261,46894 claims |
| Insmed, Inc.Arikayce | $413 | $160,14211 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,234 | $37,30399 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Tupelo
- Jaime UngoTupelo$29K
- William EdmonsonTupelo$15K
- Paul PerryTupelo$13K
- Kevin HarbourTupelo$13K
- Robert StewartTupelo$10K
- Ryan SessumsTupelo$4K
- Jose Henao CorreaTupelo$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.